| Rapid identification of potential inhibitors of SARS‐CoV‐2 main protease by deep docking of 1.3 billion compounds AT Ton, F Gentile, M Hsing, F Ban, A Cherkasov Molecular informatics 39 (8), 2000028, 2020 | 501 | 2020 |
| Deep docking: a deep learning platform for augmentation of structure based drug discovery F Gentile, V Agrawal, M Hsing, AT Ton, F Ban, U Norinder, ME Gleave, ... ACS central science 6 (6), 939-949, 2020 | 255* | 2020 |
| Crystallographic structure of wild-type SARS-CoV-2 main protease acyl-enzyme intermediate with physiological C-terminal autoprocessing site J Lee, LJ Worrall, M Vuckovic, FI Rosell, F Gentile, AT Ton, NA Caveney, ... Nature communications 11 (1), 5877, 2020 | 162 | 2020 |
| Artificial intelligence–enabled virtual screening of ultra-large chemical libraries with deep docking F Gentile, JC Yaacoub, J Gleave, M Fernandez, AT Ton, F Ban, A Stern, ... Nature Protocols 17 (3), 672-697, 2022 | 156 | 2022 |
| Automated discovery of noncovalent inhibitors of SARS-CoV-2 main protease by consensus Deep Docking of 40 billion small molecules F Gentile, M Fernandez, F Ban, AT Ton, H Mslati, CF Perez, E Leblanc, ... Chemical science 12 (48), 15960-15974, 2021 | 47 | 2021 |
| X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation J Lee, C Kenward, LJ Worrall, M Vuckovic, F Gentile, AT Ton, M Ng, ... Nature Communications 13 (1), 5196, 2022 | 40 | 2022 |
| Drugging the ‘undruggable’. therapeutic targeting of protein–DNA interactions with the use of computer-aided drug discovery methods M Radaeva, AT Ton, M Hsing, F Ban, A Cherkasov Drug Discovery Today, 2021 | 29 | 2021 |
| Targeting SARS-CoV-2 papain-like protease in the postvaccine era AT Ton, M Pandey, JR Smith, F Ban, M Fernandez, A Cherkasov Trends in Pharmacological Sciences 43 (11), 906-919, 2022 | 28 | 2022 |
| Molecular basis of interactions between SH3 domain-containing proteins and the proline-rich region of the ubiquitin ligase Itch G Desrochers, L Cappadocia, M Lussier-Price, AT Ton, R Ayoubi, ... Journal of Biological Chemistry 292 (15), 6325-6338, 2017 | 21 | 2017 |
| Dual-inhibitors of N-Myc and AURKA as potential therapy for neuroendocrine prostate cancer AT Ton, K Singh, H Morin, F Ban, E Leblanc, J Lee, N Lallous, ... International journal of molecular sciences 21 (21), 8277, 2020 | 19 | 2020 |
| A functional substitution in the L‐aromatic amino acid decarboxylase enzyme worsens somatic symptoms via a serotonergic pathway S Khoury, MH Piltonen, AT Ton, T Cole, A Samoshkin, SB Smith, I Belfer, ... Annals of neurology 86 (2), 168-180, 2019 | 12 | 2019 |
| Development of VPC-70619, a small-molecule N-Myc inhibitor as a potential therapy for neuroendocrine prostate cancer AT Ton, J Foo, K Singh, J Lee, A Kalyta, H Morin, C Perez, F Ban, ... International Journal of Molecular Sciences 23 (5), 2588, 2022 | 10 | 2022 |
| Large-scale virtual screening for the discovery of SARS-CoV-2 papain-like protease (PLpro) non-covalent inhibitors O Garland, AT Ton, S Moradi, JR Smith, S Kovacic, K Ng, M Pandey, ... Journal of Chemical Information and Modeling 63 (7), 2158-2169, 2023 | 8 | 2023 |
| A novel class of broad-spectrum active-site-directed 3C-like protease inhibitors with nanomolar antiviral activity against highly immune-evasive SARS-CoV-2 Omicron subvariants J Pérez-Vargas, LJ Worrall, AD Olmstead, AT Ton, J Lee, I Villanueva, ... Emerging microbes & infections 12 (2), 2246594, 2023 | 6 | 2023 |
| Myc-max inhibitor compound therapeutics for cancer treatment, methods and uses associated therewith A Tcherkassov, PS Rennie, F Ban, EJJ Leblanc, LA Carabet, N Lallous, ... US Patent App. 17/250,810, 2022 | 1 | 2022 |
| Inferring the selection window in antimicrobial resistance using deep mutational scanning data and biophysics-based fitness models P Dasmeh, AT Ton, C Quach, AWR Serohijos Biorxiv, 189019, 2017 | 1 | 2017 |
| Structure-based development of a novel MYC inhibitor for neuroendocrine prostate cancer J Foo, AT Ton, K Singh, F Ban, H Morin, J Lee, E LeBlanc, N Lallous, ... Cancer Research 82 (12_Supplement), 5731-5731, 2022 | | 2022 |
| Development and application of consensus hit-calling protocols for the virtual screening of ‘undruggable’and difficult drug targets AT Ton University of British Columbia, 2022 | | 2022 |
